Prior Authorization for GLP-1 Obesity Medications: A Provider's Guide | Informed Plate

← Provider resources

Clinical resource disclaimer: This guide provides general educational information about prior authorization processes and is not legal or billing advice. Payer policies change frequently — always verify current requirements directly with the payer before submitting. ICD-10 codes listed are commonly used examples; correct coding is the responsibility of the submitting provider.

How prior authorization for GLP-1 obesity medications works

Prior authorization (PA) for GLP-1 obesity medications has become nearly universal. As of 2024, over 83% of Medicare Part D plans require PA for semaglutide and tirzepatide — a dramatic jump from under 25% just one year earlier. Commercial plans have followed suit. The landscape in 2025–2026 is one of high coverage rates paired with high administrative burden.

The core logic is straightforward: the payer requires you to demonstrate that the patient meets their specific clinical criteria before authorizing the prescription. For obesity medications, this typically means documented BMI, relevant comorbidities, evidence of prior lifestyle intervention, and confirmation that the drug is being used for an FDA-approved indication. What varies significantly is the specific threshold, format, and evidence requirements between payers.

The single most important principle: PA approvals are documentation battles. A well-supported, clearly coded submission with complete documentation wins more often than an incomplete one, regardless of how medically obvious the indication is. Most denials at the first-submission level are administrative, not clinical.

The current coverage landscape (2025–2026)

Coverage and PA requirements are in significant flux. Here's what you need to know heading into 2026:

Commercial plans: Most large commercial insurers cover Wegovy and Zepbound with PA for obesity indications, but this varies enormously by employer plan. Self-insured employers set their own formulary — the same insurer may cover the drug for some employer groups and not others. Always verify benefit-specific coverage before initiating PA.
Medicare Part D: Medicare does not currently cover GLP-1 medications for obesity alone. It does cover semaglutide (Wegovy) for patients with established cardiovascular disease under the SELECT trial indication. In December 2025, CMS announced plans to expand obesity drug coverage — watch for updates in 2026.
Medicaid: Highly variable by state. Some states cover GLP-1s for obesity; many do not. Tirzepatide is more broadly covered for obstructive sleep apnea in states that follow the FDA label. Always check your state's PDL.
Step therapy: Many payers require documented failure of a lifestyle intervention program (typically 3–6 months) before approving GLP-1s. Some require prior trial of other anti-obesity medications. Document this clearly in your submission.

Blue Cross / BCBS commercial alert: Multiple Blue Cross plans dropped coverage for Wegovy, Zepbound, and Saxenda for weight loss in fully insured large group commercial plans beginning January 2025. If your patient has Blue Cross commercial coverage, verify benefit-specific coverage before initiating PA — you may be submitting into a non-covered benefit.

ICD-10 codes for GLP-1 obesity medication PA

Correct coding is the foundation of a successful PA. Use the most specific code supported by your documentation. Pair obesity codes with BMI codes and all relevant comorbidity codes — this builds the medical necessity argument directly into your claim.

Primary obesity diagnosis codes

Code	Description	When to use
E66.01	Morbid (severe) obesity due to excess calories	BMI ≥ 40, or BMI ≥ 35 with significant comorbidities. Strongest medical necessity signal.
E66.09	Other obesity due to excess calories	BMI 30–39.9. Most commonly used code for Wegovy/Zepbound PA.
E66.3	Overweight	BMI 27–29.9 with qualifying comorbidity (e.g., cardiovascular disease, hypertension).
E66.9	Obesity, unspecified	Use only if the specific type is not documented. Less preferred — specify whenever possible.

BMI codes Required by most payers

Code	BMI range	Note
Z68.30–Z68.34	30.0–34.9	Pair with E66.09. Most common range for initial PA.
Z68.35–Z68.39	35.0–39.9	Pair with E66.09 or E66.01 if significant comorbidities are present.
Z68.41–Z68.44	40.0–44.9	Pair with E66.01. Stronger medical necessity signal.
Z68.45	≥ 45	Pair with E66.01. Document current BMI in chart — most payers require measurement within 30–90 days.

High-value comorbidity codes Strengthens case

Code	Condition	Why it matters
I10	Essential hypertension	Qualifying comorbidity for BMI ≥ 27 indication; weight-related
E11.9 / E11.65	Type 2 diabetes mellitus	Supports medical necessity; separate coverage pathway for Ozempic/Mounjaro
E78.5	Hyperlipidemia, unspecified	Weight-related comorbidity that strengthens necessity
I25.10	Atherosclerotic heart disease	Required for SELECT-indication coverage (cardiovascular benefit)
G47.33	Obstructive sleep apnea	Tirzepatide (Zepbound) is FDA-approved for moderate-to-severe OSA in adults with obesity — separate coverage pathway independent of BMI thresholds
K76.0	Fatty liver (MASLD/NASH)	Supports metabolic complexity of obesity
Z79.85	Long-term use of injectable non-insulin antidiabetic drugs	Use for continuation of therapy; may reduce medical necessity denials

Coding note — Ozempic vs. Wegovy vs. Zepbound: These medications carry different approved indications that drive different coding strategies. Ozempic (semaglutide 0.5–2 mg) is approved for T2DM — code E11.x as primary. Wegovy (semaglutide 2.4 mg) is approved for obesity and cardiovascular risk reduction — code E66.x or I25.x. Zepbound (tirzepatide) is approved for obesity and moderate-to-severe OSA — code E66.x or G47.33. Using obesity (E66) as the primary code when submitting an Ozempic PA is a common cause of immediate denial. Additionally, note that insurance coverage for Ozempic for prediabetes has been largely unavailable since 2024 — submit with T2DM documentation or route to an obesity-indicated agent.

Clinical tip — code contraindications to non-GLP-1 therapy proactively: One of the most effective strategies to avoid step therapy requirements is to document, upfront, any conditions that would make alternative anti-obesity medications contraindicated or inappropriate for this patient. Payers sometimes push for stimulant-based options (phentermine, Qsymia) before approving GLP-1s — but there are many patients for whom stimulants are clearly off the table. If your patient has ADHD and is on Adderall, include the ADHD ICD-10 code and explicitly note that an additional stimulant medication is contraindicated. Anxiety, insomnia, paroxysmal SVT, and other cardiovascular arrhythmias are also contraindications to stimulant therapy — document these when present. Similarly, if a payer is pushing orlistat, clearly document the patient's daily schedule — work demands, caregiving responsibilities, or any situation where frequent unplanned bathroom trips would be disruptive or untenable. The goal is to make it easier for the reviewer to approve GLP-1 therapy than to require additional steps. Relevant ICD-10 codes to consider including when applicable:

F90.x — ADHD (contraindication to additional stimulant if already on stimulant medication)
F41.1 — Generalized anxiety disorder (contraindication to stimulants)
G47.00 — Insomnia (contraindication to stimulants)
I47.1 — Supraventricular tachycardia / paroxysmal SVT (contraindication to stimulants)
I10 + any arrhythmia code — cardiovascular conditions that preclude stimulant use
Z55–Z56 — education/literacy barriers and work circumstances that make orlistat impractical (frequent unplanned restroom stops)

Documentation checklist

Incomplete documentation is the most common cause of preventable PA denials. Before submitting, confirm you have each of the following:

✓

Current height, weight, and BMI — dated within 30–90 days

Most payers specify a recency requirement. Document in the chart as a vital sign, not just calculated. UnitedHealthcare and Cigna specifically require current and baseline weight within 30 days of submission.

✓

Confirmed obesity or overweight diagnosis with comorbidity

The diagnosis must be explicitly documented in your notes — not just coded. Write "obesity (BMI 37.2)" or "overweight with hypertension" in your assessment. Payers look for this in chart notes as well as the claim.

✓

Documentation of prior lifestyle intervention

Most payers require evidence of a structured diet and/or exercise program — typically 3–6 months of documented effort. "Patient advised to diet and exercise" is insufficient — document the specific intervention, duration, and outcome.

✓

All relevant comorbidities documented

List all active, obesity-related diagnoses in your assessment: hypertension, T2DM, dyslipidemia, OSA, cardiovascular disease, MASLD. Each one strengthens medical necessity.

✓

Relevant lab values — if available

HbA1c (if T2DM/prediabetes), lipid panel, fasting glucose. These aren't always required but strengthen the case significantly. Cigna specifies HbA1c requirements for the cardiovascular indication.

✓

Prescriber has established, in-person relationship with patient

Multiple payers (Blue Cross, UHC) have added requirements that the prescribing provider has seen the patient in person. Telehealth-only prescriptions are receiving increased scrutiny. Document in-person visit dates.

✓

Prior therapy history — if step therapy required

If the payer requires step therapy, document what was tried, for how long, and why it was insufficient. Include dates and response. Format: "Patient tried Qsymia × 3 months with inadequate response, discontinued due to [reason]."

★

For renewals and GLP-1 switches: check "continuation of therapy"

This is one of the most common and consequential administrative errors in GLP-1 PA management. Always select "continuation of therapy" on renewal — never submit as a new request. A patient who has responded well will have a lower BMI than when they started. Submitted as new, the insurer sees a BMI that no longer meets their initial threshold and denies coverage — because the medication is working.

This applies equally when switching between GLP-1 agents. If a patient is transitioning from semaglutide to tirzepatide — or any GLP-1 to another — explicitly state in the submission: "This is continuation of GLP-1 therapy. Patient has been on [prior medication] since [date]. Reason for switch: [no longer tolerating X / inadequate response after X weeks / formulary change / contraindication to current agent]." Without this framing, the payer may treat it as a first-time GLP-1 request, apply step therapy requirements, or deny based on current BMI — even though the clinical rationale for ongoing therapy is unchanged.

Step-by-step PA submission

Verify benefit coverage — or just submit and find out

In an ideal workflow, you'd call member services or check the payer's provider portal to confirm whether the specific drug and formulation is covered before submitting. In practice, patients rarely have the time or inclination to call their insurance to investigate GLP-1 coverage, and administrative staff often don't either. The honest reality is that it is frequently faster to simply submit the PA and let the approval or denial tell you what the coverage parameters are.

What matters is being transparent with patients upfront: insurance coverage for GLP-1 obesity medications is inconsistent and plan-specific. We will do our best to get coverage approved if the medication is included in their plan. If it turns out to be a plan exclusion — not just a denial, but a benefit exclusion — there is nothing to appeal. No amount of documentation or peer-to-peer calls will override a plan that simply does not cover obesity medications. In that case, the conversation shifts to self-pay options, manufacturer savings programs (Novo Nordisk Care, Lilly Cares), or alternative treatment approaches.

A common point of patient confusion worth addressing proactively: many patients will come in having already called their insurance and been told "yes, we cover GLP-1 medications — your doctor should prescribe Ozempic or Mounjaro." This is accurate, but incomplete. Ozempic (semaglutide) and Mounjaro (tirzepatide) are the diabetes-indicated formulations of these drugs — they are covered because the patient's plan covers GLP-1s for type 2 diabetes. A patient without a T2DM diagnosis sitting in front of you is not eligible for these medications under that coverage. Educate patients clearly on the distinction before they arrive expecting a specific prescription: Wegovy and Zepbound are the weight loss/OSA/cardiovascular risk-indicated formulations, and those may or may not be covered by their plan regardless of what the general GLP-1 coverage inquiry suggested.

Use CoverMyMeds or the payer portal — not fax when possible

Electronic PA submission is faster, trackable, and reduces transcription errors. Fax is slower and has no tracking. Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) both have PA support lines and resources via their provider portals.

Front-load your documentation

Don't wait for the payer to request additional information. Attach your chart note, weight history, labs, and a brief letter of medical necessity with the initial submission. This is the single most effective way to avoid the Request for Additional Information (RAI) cycle that adds weeks to the process.

Document your submission date and reference number

Record the submission date, reference number, and expected turnaround time. The CMS prior authorization rule effective 2026 requires most payers to respond to standard PA requests within 7 days and urgent requests within 72 hours.

Set patient expectations before they leave the office

Tell the patient: "We're submitting a prior authorization today. It typically takes 3–14 business days. We'll contact you when we have a decision. If it's denied, we will appeal." Don't let the patient call the pharmacy expecting a filled prescription in 24 hours.

Common denial reasons — and how to appeal each one

Not medically necessary

The most common catch-all denial. Usually means documentation was insufficient or didn't match the payer's specific policy criteria.

→ Appeal with complete chart note, BMI documentation, comorbidity list, and a targeted LMN referencing their specific policy criteria.

Step therapy not met

Payer requires prior trial of another anti-obesity medication or a documented 3–6 month lifestyle intervention not reflected in the submission.

→ Submit detailed history of prior interventions with dates. If requesting a step therapy exception, provide specific clinical rationale.

Drug not on formulary / non-preferred agent

The payer covers a different GLP-1 than what was prescribed, or the drug is excluded from this patient's specific benefit plan.

→ Request a formulary exception. If obesity meds are plan-excluded entirely, redirect to manufacturer patient assistance programs (Novo Nordisk Care, Lilly Cares).

Indication mismatch

Ozempic coded as obesity treatment, or off-label use coded without sufficient clinical rationale.

→ Re-submit with correct drug-indication coding. For off-label use, provide clinical literature support and a detailed LMN explaining why on-label alternatives are inadequate.

BMI threshold not met

Documented BMI is below the payer's threshold, documentation is outdated, or — on renewals — the patient's BMI has improved because the medication is working.

→ For renewals, submit as continuation of therapy and document starting BMI, percent weight loss, and ongoing clinical rationale. Never submit a renewal as a new request.

No established prescriber relationship

Payer requires an in-person encounter with the prescribing provider, or the prescriber is not enrolled as an approved prescriber for this drug class.

→ Document in-person visit date in appeal. Verify prescriber enrollment if needed. Telehealth-only prescriptions are receiving increased scrutiny from most major payers.

The peer-to-peer call

If a first-level appeal is denied, request a peer-to-peer (P2P) review — a direct phone call between you and the payer's medical reviewer. In practice, phone appeals consistently outperform written appeals for GLP-1 obesity medications. You can address the reviewer's specific objections in real time, make the case for your patient directly, and respond to questions that a written submission can't anticipate. If you have the capacity, always request the phone review over a written appeal for a denial you believe is clinically unjustified.

Key points to make on the call:

Obesity is a chronic disease with documented cardiometabolic complications in this patient — name them specifically
Prior lifestyle interventions were documented and clinically insufficient — cite dates and response
Any conditions present that make alternative medications contraindicated (stimulants, orlistat) — make this case explicitly if it applies
Clinical guidelines from the Obesity Medicine Association, AHA/ACC, and the 2025 WHO GLP-1 guideline support pharmacotherapy as a standard of care for this patient
For continuations: the patient's current BMI reflects medication efficacy, not lack of medical need — ongoing treatment is required to maintain response

External review rights: If an internal appeal is denied, patients have the right to request an independent external review. For commercial plans regulated under the ACA, this is a federal right. Pursue this option when the clinical case is strong and the denial appears to contradict the payer's own stated criteria.

Payer-specific tips

Payer	Coverage	Key requirements	Notes
UnitedHealthcare	Covers	BMI ≥ 30 or ≥ 27 + comorbidity; in-person visit required; current + baseline weight within 30 days	Strong documentation of lifestyle intervention history required. New PA criteria began August 2024.
Cigna	Covers	BMI ≥ 30 or ≥ 27 + comorbidity; diet program × 3–6 months; HbA1c for CV indication	PA approval typically 1 year. Continuation criteria require documented weight loss response (typically ≥ 5% at 12–16 weeks). Plan ahead for renewal documentation.
Aetna	Covers	BMI ≥ 30 or ≥ 27 + comorbidity; comprehensive weight management program documented	Multiple benefit plans — verify specific plan. Some self-insured employers have exclusions. Step therapy requirements vary by plan.
BCBS / Blue Cross	Varies by plan	Varies significantly — many fully insured large group plans dropped obesity drug coverage January 2025	Always verify plan-specific benefit before submitting. Some BCBS plans still cover; many do not for weight loss. Medicare Advantage BCBS plans may have different criteria.
Medicare Part D	Limited	Covers for T2DM or established CVD (SELECT indication) only — not obesity alone currently	CMS proposed expansion in December 2025 — watch for updates. For cardiovascular indication, document prior MI, stroke, or peripheral arterial disease. Use I25.10 or I63.x codes.
Medicare Advantage	Plan-dependent	Some MA plans have added obesity drug coverage beyond standard Medicare Part D	PA rates in MA plans rose sharply to 83%+ in 2024. Always submit with complete documentation. Verify per plan.
Medicaid (state-dependent)	Highly variable	Varies by state PDL; some cover tirzepatide for moderate-to-severe OSA; few cover for obesity alone	Pennsylvania and California Medicaid restricted obesity-indication coverage in 2025. Tirzepatide for OSA may have a more favorable separate coverage pathway. Check your state's current PDL.

Letter of medical necessity template

A letter of medical necessity (LMN) is your strongest appeal tool and a valuable addition to any initial submission for complex cases. Adapt the template below with patient-specific information. Keep it under 2 pages — focused, specific, and tied directly to the payer's stated criteria.

Letter of medical necessity — Wegovy® / Zepbound® template

Date: [Date]
Re: [Patient Name] | DOB: [DOB] | Member ID: [ID]
Requested medication: [Wegovy® semaglutide 2.4 mg / Zepbound® tirzepatide]
Prescribing provider: [Your name, credentials, NPI]

To Whom It May Concern:

I am writing to request prior authorization for [medication name] for my patient [Patient Name], who I have treated in person since [date of established care]. This patient meets all criteria for this medication as established by current clinical guidelines and, to my understanding, your plan's coverage policy.

Clinical presentation:
[Patient Name] is a [age]-year-old [sex] with a current BMI of [BMI] ([height/weight]), meeting criteria for [obesity class I/II/III or overweight]. Active obesity-related comorbidities include: [list: e.g., type 2 diabetes mellitus (HbA1c [X]%), hypertension, hyperlipidemia, obstructive sleep apnea]. These conditions are directly associated with the patient's elevated body weight and are expected to improve with clinically significant weight reduction.

Prior interventions:
This patient has made documented efforts at weight management through: [e.g., structured diet program from MM/YY to MM/YY; nutritional counseling × N sessions; trial of prior medication from MM/YY to MM/YY with inadequate response / side effects]. Despite these efforts, the patient has been unable to achieve or sustain clinically meaningful weight loss sufficient to improve metabolic comorbidities.

Medical necessity:
Pharmacotherapy with [medication] is medically necessary based on: (1) established obesity with weight-related comorbidities refractory to lifestyle intervention alone; (2) clinical guidelines from the Obesity Medicine Association, AHA/ACC, and the 2025 WHO GLP-1 guideline supporting pharmacotherapy as a standard of care for chronic obesity management; and (3) the patient's elevated cardiovascular and metabolic risk, which is expected to be meaningfully reduced by the documented efficacy of this medication class.

Expected outcomes:
Clinical trials demonstrate average weight reduction of 15–21% at 68–72 weeks with semaglutide and tirzepatide, with corresponding improvements in blood pressure, glycemic control, lipid profile, and cardiovascular event risk. For this patient, meaningful weight reduction is expected to [improve HbA1c / reduce antihypertensive burden / reduce cardiovascular risk / improve OSA severity — tailor to patient].

I am available for a peer-to-peer discussion at [phone number] should you have clinical questions regarding this request. Thank you for your consideration.

Sincerely,
[Your name, credentials]
[Practice name, address, phone, NPI]

Setting patient expectations around PA timelines

One of the most consistent sources of patient frustration with GLP-1 prescribing is PA delays that weren't communicated in advance. A brief, clear conversation before the patient leaves your office prevents most of this.

Typical PA timeline

Day 1

PA submitted. Patient informed — no prescription filled yet.

Days 1–3

Payer reviews. May request additional information (RAI).

Days 3–7

Decision typically returned. Approved → specialty pharmacy.

Days 7–14

If denied → first-level appeal submitted.

Ongoing

PA typically approved 6–12 months — approval is not a guarantee of continued coverage.

Script for the office visit: "We're submitting the prior authorization today. Most decisions come back within 3–7 business days, though it can take up to 2 weeks with some insurers. Your pharmacy won't be able to fill the prescription until we have approval. If it's denied — which does happen — we will appeal, and those appeals are often successful. We'll keep you updated."

What approval actually means — and what it doesn't

In clinical practice as of 2026, PA approvals for GLP-1 obesity medications are typically valid for 6–12 months, and that window can close early without warning. It is not uncommon for a patient to receive approval, start therapy and begin responding well, only to have the insurer reverse coverage 2–3 months in — citing a policy change, formulary update, or revised criteria. This happens. It is not a billing error.

Set this expectation explicitly with patients before they start: "Your insurance has approved this medication, which is great. I want you to know that this approval typically lasts 6–12 months, and occasionally insurance companies do change their coverage mid-year. If that happens, we'll work through it — but I don't want you to be caught off guard. Let's also make sure we're building dietary and lifestyle habits that support your results independent of the medication, so any interruption in coverage doesn't set you back significantly."

Insurer-mandated programs: the new PA condition

An increasingly common PA requirement — particularly from larger commercial plans — is mandatory enrollment in the insurer's own proprietary weight management program as a condition of coverage. Requirements commonly include monthly or weekly visits with an insurer-provided dietitian, regular weight check-ins using a smart scale the insurer monitors remotely, completion of behavioral coaching modules, and documented "engagement" as a condition of prescription renewal. Patients who don't comply may lose coverage mid-cycle — make sure they understand any program enrollment obligations at the time of approval.

A note on equitable treatment: We do not require patients with hypertension to enroll in an insurer-managed lifestyle program before prescribing antihypertensives. We do not require patients with depression to attend insurer-run therapy sessions before approving SSRIs. The additional barriers imposed for obesity pharmacotherapy reflect a persistent payer-level assumption that obesity is a behavioral failure requiring surveillance rather than a chronic disease requiring treatment. This framework perpetuates the same stigma that makes many patients reluctant to seek care. Knowing this exists helps you frame the conversation with patients who may internalize these hoops as judgment rather than policy.

Continuation of therapy — plan ahead: Build continuation documentation into your standard follow-up workflow before the PA expiration date, not after. At every visit, document current weight, percent weight change from baseline, and trend in relevant comorbidities (blood pressure, HbA1c, lipids). Payers increasingly require demonstrated response — typically ≥ 5% weight loss at 12–16 weeks — for renewal. If a patient is responding but slowly, document clinical benefit beyond the scale: improved blood pressure, reduced medication burden, improved sleep apnea symptoms.

📊

Free tool for your patients

GLP-1 Side Effect Tracker

Patients log symptoms over time — you get structured data to support continuation documentation at follow-up visits.

→

References and sources

Liu X, et al. (2025). Coverage and prior authorization policies for semaglutide and tirzepatide in Medicare Part D plans. JAMA Network Open. PMC12397888
Cigna National Formulary Coverage. Weight Loss — GLP-1 Agonists Prior Authorization Policy. 2025.
UnitedHealthcare. Weight Loss — GLP-1 Agonists PA Notification. August 2024.
Blue Cross Blue Shield of Michigan. Provider Alert: Changes to GLP-1 Weight Loss Drug Coverage. June 2024.
Eli Lilly. Zepbound Prior Authorization Resource Guide. 2025.
Novo Nordisk. Wegovy Frequently Used ICD-10 Codes. January 2025.
Kushner RF, Almandoz JP, Rubino DM. (2025). Managing adverse effects of incretin-based medications for obesity. JAMA. 334(9):822–823.
Celletti F, Farrar J, De Regil L. (2025). WHO guideline on the use of GLP-1 therapies for the treatment of obesity in adults. JAMA. Published online December 1, 2025.
CMS. (December 2025). Proposed rule on Medicare GLP-1 obesity drug coverage expansion. CMS.gov.
ICD-10-CM 2026. E66 — Overweight and obesity. icd10data.com.

How to prevent muscle loss on GLP-1 medications — protein, resistance training, and timing

→